about
Fluphenazine decanoate (depot) and enanthate for schizophreniaDepot fluphenazine decanoate and enanthate for schizophreniaDepot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature.Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine.Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system.Early intervention in schizophrenia.Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies.Schizophrenia and antipsychotic somatic treatment.Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.Low dose maintenance medication for schizophrenia.Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.Low dose maintenance medication for schizophrenia.Assessment of interpersonal problem-solving skills.Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.Extrapyramidal symptoms and residual psychopathology with low-dose neuroleptics.Some factors relating to satisfactory post-discharge community maintenance of chronic psychotic patients.A comprehensive treatment program for schizophrenia and chronic mental illness.Social skills and relapse history in outpatient schizophrenics.
P2860
Q24188205-4E44C41A-8A47-4518-851E-A2D3000DB39EQ24247121-D74B3B02-456D-46CE-B147-30DC3A76BE10Q33785814-AD9659FA-0B92-471D-875A-D4DD7B72DA6FQ33908794-3AA8CE6A-8520-455C-A0A2-8ACEA13047A5Q34315836-F7ECA9E8-8ECB-4BF0-9E5A-68F046F1BF68Q34418847-463F6ACC-4AD0-4AE4-9518-4D0328A17E9CQ37760926-3B28D1A7-5E58-4176-BF3D-1124CBD3DEF1Q38363963-3158A0F8-7577-4E4F-8F38-4CBBC89DA37EQ38984616-64A02408-9C67-47FE-A492-4205FD218867Q40785111-831DFC30-9321-4CF9-A648-5E393BA77949Q40960279-4DB7F928-EDF0-43E9-9EFC-60E53C38FBB5Q41459295-70BA798A-DA35-4D7A-A092-3E9D42E82E6CQ41846717-D61E7FC7-FBF0-40E3-81D7-2EBE7207475EQ41886551-6E778623-278C-4493-91F9-07195B88D61AQ42610530-0A898E3E-2179-4938-9BF2-1E251BDE44CAQ42690298-DBFD5B5C-5B2B-4BB2-9F4A-6205545CF55CQ44032629-FFB9F05B-099E-45D5-ABB0-7E4D7E29BFF5Q46886092-0CFC6CDE-5CE0-4A2C-9EBE-2BE719BC0012Q51952586-163D216B-DF80-4359-990B-B26A54F8D4ACQ52059193-3EC82290-B1CE-4338-960E-2328CAE9811CQ52081045-608A9713-5168-4FB2-AB5D-49F10D646E43Q52239647-6A1A5B32-6C70-4AF4-A0A0-85454C22461B
P2860
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Costs and benefits of two doses of fluphenazine.
@en
Costs and benefits of two doses of fluphenazine.
@nl
type
label
Costs and benefits of two doses of fluphenazine.
@en
Costs and benefits of two doses of fluphenazine.
@nl
prefLabel
Costs and benefits of two doses of fluphenazine.
@en
Costs and benefits of two doses of fluphenazine.
@nl
P2093
P1433
P1476
Costs and benefits of two doses of fluphenazine.
@en
P2093
McKenzie J
Van Putten T
P304
P356
10.1001/ARCHPSYC.1983.01790220015002
P407
P577
1984-11-01T00:00:00Z